Until now, no randomised trial had compared Tamiflu with no antiviral in critically ill patients.
The international REMAP-CAP trial has now done that—and found no benefit. More patients died with Tamiflu than without it.
2 Replies to “The Sound Of Settled Science”
Leave a Reply
You must be logged in to post a comment.
The Great Replacement is rather impatient.
Here’s two more:
https://voices.nejm.org/doi/full/10.1056/VOICESpost2600044
Paul Sax Aug 18, 2026 _ Oseltamivir Flops in the Critically Ill
Not only was oseltamivir ineffective, but there was a good chance it may even have made outcomes worse. And even though we’re just seeing the study in preprint right now, there’s every reason to take the results seriously:
https://emcrit.org/pulmcrit/remap-cap-oseltamivir/
June 21, 2026 by Josh Farkas _ PulmCrit: Is oseltamivir assassinating ICU patients?
The study concludes that the likelihood of causing increased mortality is 98.3%
“More patients died with Tamiflu than without it.”
Marmots hardest hit.
Now do Ivermectin and Hydroxychloroquin.